The phase III MARIPOSA study's time to symptomatic progression (TTSP) data showed a median of 43.6 months with first-line amivantamab plus lazertinib versus 29.3 months with osimertinib (HR 0.69, 95% CI 0.57–0.83) in EGFR mutant NSCLC (final protocol-specified OS analysis, median follow-up 37.8 months; TTSP is a supportive endpoint — the primary endpoint was PFS). The thoracic oncology community is also discussing key gaps in managing EGFR-positive disease, such as patient selection for combination therapy versus TKI monotherapy. Other topics include the management of borderline resectable NSCLC with a 'systemic therapy first' approach.
“Report on time to symptomatic progression from phase III MARIPOSA study in EGFR mutant NSCLC available. Median was 43.6m with 1L amivantamab + lazertinib compared to 29.3m with osimertinib (HR 0.69).”
— @StephenVLiu · MARIPOSA study · View post ↗📌 Amplified by @KolPulseAI
“Top 5 gaps in EGFR+ lung cancer today? 1. Who really needs combo therapy? 2. How do we choose b/w frontline combos? 3. Is TKI monotherapy still enough? 4. Can we reduce toxicity w/o sacrificing efficacy? 5. Should we treat earlier to improve long-term outcomes?”
— @lungoncdoc · EGFR+ NSCLC Gaps · View post ↗📌 Amplified by @KolPulseAI
“Borderline resectable NSCLC - the path forward? @BrendonStilesMD 1. Think biology > anatomy. 2. Systemic therapy first. 3. Always reassess resectability. 4. Don't label unresectable too early. 5. Right patient. Right therapy. Right time.”
— @lungoncdoc · Borderline Resectable NSCLC · View post ↗📌 Amplified by @KolPulseAI
The European Commission approved camizestrant (Etcamah) on 23 July 2026, in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), for adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an ESR1 mutation and without disease progression during first-line endocrine therapy — the SERENA-6 setting. ⚠️ Camizestrant is not FDA approved; the US application remains under review. Its implementation will require sequential ctDNA testing without PD, which @PTarantinoMD notes 'may not be immediately available across 🇪🇺.' Separately, @PTarantinoMD pushed back on the framing of 'HER2-low is a new breast cancer subtype.'
“Camizestrant now approved in Europe.”
— @PTarantinoMD · Camizestrant approval · View post ↗📌 Amplified by @KolPulseAI
“Though implementation of cami will require sequential ctDNA testing without PD, which may not be immediately available across 🇪🇺.”
— @PTarantinoMD · Camizestrant implementation · View post ↗📌 Amplified by @KolPulseAI
“Me hearing someone say “HER2-low is a new breast cancer subtype.””
— @PTarantinoMD · HER2-low classification · View post ↗The U.S. FDA has accepted the New Drug Application (NDA) for daraxonrasib for review in previously treated metastatic pancreatic cancer, based on RASolute 302. ⚠️ Daraxonrasib is investigational and not FDA approved; NDA acceptance starts the review clock only. Separately, discussion continues on the role of radiotherapy (RT) in rectal cancer, with commentary rejecting "RT omission dogma" in favor of tailored RT and dose escalation to avoid surgical mutilation and systemic overtreatment. A new review also highlights the shift in hepatocellular carcinoma (HCC) management toward a personalized, multimodal continuum.
“Revolution Medicines’ (@RevMedicines) New Drug Application (NDA) for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic #PancreaticCancer”
— @Aiims1742 · Daraxonrasib NDA · View post ↗📌 Amplified by @KolPulseAI
“We reject the RT omission dogma.The future of rectal cancer care lies in tailored RT and dose escalation,ensuring that we protect our pts not only from surgical mutilation but also from the systemic overtreatment that threatens their QoL and OS.”
— @alongi_filippo · Rectal Cancer Radiotherapy · View post ↗
“HCC management is shifting toward a personalized, multimodal continuum, a 🇨🇦 perspective”
— @ArndtVogel · HCC Management · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Data from two trials, both now published in the NEJM, establish perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC). In cisplatin-eligible patients, KEYNOTE-B15/EV-304 showed improved 2-year event-free survival (79.4% vs 66.2%; HR 0.53), overall survival (HR 0.65) and pathological complete response (55.8% vs 32.5%) versus neoadjuvant cisplatin/gemcitabine (NEJM, EV-304; N=808). In cisplatin-ineligible patients, KEYNOTE-905/EV-303 demonstrated improved 2-year EFS (74.7% vs 39.4%; HR 0.40, 95% CI 0.28–0.57), overall survival (HR 0.50; 2-year OS 79.7% vs 63.1%) and pathological complete response (57.1% vs 8.6%) versus surgery alone (NEJM, EV-303; N=344). ✅ Perioperative enfortumab vedotin-ejfv (Padcev) + pembrolizumab is FDA-approved for adults with MIBC undergoing radical cystectomy — cisplatin-ineligible since 21 Nov 2025 (EV-303), expanded to cisplatin-eligible patients on 10 Jul 2026 (EV-304). Grade ≥3 treatment-emergent adverse events were more frequent with EV+pembrolizumab (75.7% vs 67.2%); treatment-related deaths were rare in both arms (0.5% vs 0.3%), with skin reactions (63.5%) and peripheral neuropathy (36%) the most common EV-related events of special interest. Both trials enrolled patients proceeding to radical cystectomy; neither evaluated bladder-preservation/trimodality approaches.
“Every EV RIII study to date has ⬆️ OS vs SOC.”
— @tompowles1 · Enfortumab Vedotin efficacy · View post ↗📌 Amplified by @KolPulseAI
“The perioperative standard now extends to all MIBC patients candidates for cystectomy.”
— @drenriquegrande · MIBC standard of care · View post ↗“KEYNOTE-905/EV-303 in @NEJM: perioperative enfortumab vedotin + pembrolizumab vs surgery alone in cisplatin-ineligible MIBC (n=344).”
— @drenriquegrande · KEYNOTE-905/EV-303 in NEJM · View post ↗
““…focal therapy effectively treats prostate cancer, keeping patients cancer free ten years after treatment.” This is, again, clear misinformation based on the data presented.”
— @jryckman3 · Prostate cancer focal therapy debate · View post ↗📌 Amplified by @KolPulseAI
“After >20 years, a non-platinum perioperative regimen beats cisplatin-based chemotherapy in resectable MIBC.”
— @Adam_Weiner535 · Perioperative MIBC standard · View post ↗📌 Amplified by @KolPulseAI
J&J reported topline Phase 3 MonumenTAL-6 results on 23 July 2026: teclistamab + talquetamab reduced the risk of progression or death by 89% (HR 0.11) and the risk of death by 62% (HR 0.38) versus investigator's-choice standard of care in relapsed/refractory myeloma with 1–4 prior lines, exposed to both anti-CD38 therapy and lenalidomide. ⚠️ Investigational — the dual-bispecific combination is not FDA approved in this setting (J&J topline press release, 23 Jul 2026). Separately, design details from the GO39775 phase 1 trial were shared, noting it enrolled a heavily pretreated population where 89.5% of patients were triple-class refractory and 47.5% had prior BCMA-targeted therapy.
“Phase 3 readout from MonumenTAL-6 — and the effect size here is hard to ignore.”
— @kansagraMD · MonumenTAL-6 trial · View post ↗📌 Amplified by @KolPulseAI
“- 89.5% triple-class refractory - 72.5% penta-drug refractory - 47.5% had prior BCMA-targeted therapy”
— @Abdallah81MD · GO39775 trial population · View post ↗
“100% agree, for those of us who have used this drug, we wish the development would move faster. It is just a great non-BCMA target.”
— @HiraSMian · Non-BCMA targets · View post ↗📌 Amplified by @KolPulseAI
“ToxCheck: Acute & Chronic side effects that we see (+ clinical pearls) w/ CAR-Ts in Multiple Myeloma w/ @Ccostello7 & @JoshuaRichterMD”
— @OncBrothers · CAR-T side effects · View post ↗The phase III MATRix/IELSG43 trial is providing guidance on consolidation therapy for fit patients with Primary CNS Lymphoma, comparing HCT-ASCT to non-myeloablative R-DeVIC after MATRix induction. Additionally, a new meta-analysis details outcomes for loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including in the post-CAR T-cell therapy setting.
“After MATRix induction, should fit PCNSL patients receive HCT-ASCT or non-myeloablative R-DeVIC consolidation?”
— @DrRishabhOnco · MATRix/IELSG43 trial · View post ↗
“Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis”
— @JournalCancer · loncastuximab tesirine · View post ↗
“Mapping the capacity for geriatric blood Cancer Care in Latin America: A cross- sectional survey of current status and future priorities”
— @DrRaulCordoba · Geriatric Hematology · View post ↗